Legg R F, Sclar D A, Nemec N L, Tarnai J, Mackowiak J I
Center for Health Services Research & Policy, Qual-Med Health Plan of Washington, Inc., Inland Northwest Division, Spokane, Wash, USA.
J Occup Environ Med. 1997 Jul;39(7):652-7. doi: 10.1097/00043764-199707000-00010.
Benefit and occupational health managers need information on whether new treatments, such as sumatriptan, for migraine headache improve organizational or individual performance. A work productivity outcomes assessment was conducted among sumatriptan-using employees of an Independent Practice Association-health maintenance organization population. Of the 164 sumatriptan users, 101 full-time employees were surveyed by telephone once in an open-label, before-after design. The results revealed that lost labor costs, a function of days missed from work and reduced productivity at work as a result of migraine, were decreased after sumatriptan treatment initiation. Incremental benefit of this reduction in lost productivity is valued at $435/month per employee. The sumatriptan cost associated with this benefit is $43.78/month. The benefit-to-cost ratio is 10:1. Other costs and benefits were excluded. In conclusion, the availability of sumatriptan for migraine headache treatments in this IPA-HMO resulted in improved work productivity and had a net benefit for the employer.
福利与职业健康经理需要了解新的治疗方法，如用于偏头痛治疗的舒马曲坦，是否能提高组织或个人绩效。对一个独立执业协会-健康维护组织中的舒马曲坦使用者进行了工作效率结果评估。在164名舒马曲坦使用者中，采用开放标签的前后对照设计，通过电话对101名全职员工进行了一次调查。结果显示，因偏头痛导致的误工天数和工作效率降低所产生的劳动力成本损失，在开始使用舒马曲坦治疗后有所减少。每名员工因生产率提高而带来的额外收益估计为每月435美元。与这一收益相关的舒马曲坦成本为每月43.78美元。效益成本比为10:1。其他成本和收益未计算在内。总之，在这个独立执业协会-健康维护组织中，使用舒马曲坦治疗偏头痛提高了工作效率，对雇主来说有净收益。
